drugset / Trial / NCT00378352

REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction

NCT00378352

Phase 2 Completed 223 enrolled National Institute on Aging (NIA)
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate whether erythropoietin can help limit the damage to the heart in patients with acute heart attacks.

Timeline

Start
2005-09
Primary completion
2009-07
Completion
2011-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator epoetin alfa Protein / enzyme biologic 60000 iu Intravenous